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Summary
Background and objectives Growth and ﬁnal height are of major concern in children with ESRD. This
study sought to describe the distribution of adult height of patients who started renal replacement
therapy (RRT) during childhood and to identify determinants of ﬁnal height in a large cohort of RRT
children.
Design, setting, participants, & measurements A total of 1612 patients from 20 European countries who
started RRT before 19 years of age and reached ﬁnal height between 1990 and 2011 were included. Linear
regression analyses were performed to calculate adjusted mean ﬁnal height SD score (SDS) and to investigate
its potential determinants.
Results The median ﬁnal height SDS was21.65 (median of 168 cm in boys and 155 cm in girls). Fifty-ﬁve percent
of patients attained an adult height within the normal range. Adjusted for age at start of RRT and primary
renal diseases, ﬁnal height increased signiﬁcantly over time from22.06 SDS in children who reached adulthood
in 1990–1995 to 21.33 SDS among those reaching adulthood in 2006–2011. Older age at start of RRT, more
recent period of start of RRT, cumulative percentage time on a functioning graft, and greater height SDS at
initiation of RRT were independently associated with a higher ﬁnal height SDS. Patients with congenital
anomalies of the kidney and urinary tract and metabolic disorders had a lower ﬁnal height than those with
other primary renal diseases.
ConclusionsAlthough ﬁnal height remains suboptimal in children with ESRD, it has consistently improved over
time.
Clin J Am Soc Nephrol 9: 92–99, 2014. doi: 10.2215/CJN.00890113
Introduction
Growth failure remains one of the major long-term
challenges in the management of childhood-onset
ESRD. Poor growth in children with ESRD is multi-
factorial and inﬂuenced by nutritional, metabolic, and
hormonal alterations (1–3) and has been associated
with an increased risk of hospitalization and death
(4). Short stature has major consequences for quality
of life and self-esteem; more than one third of young
adults with childhood-onset ESRD report to be dis-
satisﬁed with their body height (5). Short adult height
is associated with major shortcomings in social and
work life such as a lower level of education, a lower
level of employment and a lower chance of being
married (6). Achieving a normal ﬁnal height is
therefore a crucial issue for children on renal replace-
ment therapy (RRT). Improvements in the manage-
ment of CKD-related growth failure have led to
better height attainment at the time of renal trans-
plantation but following transplantation, growth is
generally not sufﬁcient to compensate for the deﬁcit
that has been acquired before transplantation (7,8).
In children, height is reported in SD scores (SDS)
from the general population. In recent years, several
single-center reports have speciﬁcally addressed ﬁnal
height after transplantation in childhood (9–13). The
proportion of patients who achieved a ﬁnal height
within the normal range ranged from 47% to 75%,
which appears considerably improved over early re-
ports in which normal adult height was achieved in
only 23%–38% (14,15). Growth is a marker of quality
of care in childhood CKD and ESRD. Through im-
provement in the management of children with kid-
ney diseases over decades, growth failure and
therefore adult short stature seem to be decreasing in
this population. In this study, we used the population-
based dataset of the European Society for Pediatric
Nephrology/European Renal Association and Euro-
pean Dialysis and Transplant Association (ESPN/
ERA-EDTA) registry to describe the ﬁnal height dis-
tribution of patients who started RRT while in pedi-
atric care in Europe, to analyze trends over time and
to identify potential determinants of ﬁnal height
SDS.
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Methods
Data Collection
This study used data recorded in the ESPN/ERA-EDTA
Registry. Within the registry, clinical data are collected
annually as reported elsewhere (16,17). Data obtained for
the purpose of this study included date of birth, sex, pri-
mary renal disease, date of start of RRT, treatment modal-
ity (hemodialysis [HD], peritoneal dialysis [PD], or
transplantation) and dates of change in treatment modal-
ity, donor source, height at start of RRT and at last follow-
up. We included patients who started RRT at ,19 years of
age and reached documented ﬁnal height between January
1, 1990, and December 31, 2011. This included data from
the following 20 countries and periods of reaching ﬁnal
height: Belarus (2010), Czech Republic (2007–2010), Esto-
nia (2010), Finland (1992–2009), France (2004–2010),
Greece (2010–2011), Hungary (2010–2011), Iceland (2009),
Italy (1990–2011), Lithuania (2010–2011), the Netherlands
(2008–2009), Norway (2008–2010), Poland (1991–2011),
Portugal (2008–2010), Serbia (1997–2011), Slovakia (2010),
Slovenia (2010), Spain (1990–2011), Switzerland (1990–
2009), and the United Kingdom (1992–2010).
Definition of Variables
Height SDS was calculated according to recent national
growth charts whenever available (18–25), or to newly de-
veloped northern and southern European growth charts
(26) for countries where recent growth reference data are
unavailable. Height SDS values were calculated by the fol-
lowing equation:
SDS5ðindividual  patient  values    mean  values  for  age
   and   sex matched   healthy  peersÞ=SDS   values  for  age
   and   sex matched   healthy  peers:
Growth retardation was deﬁned by a height SDS, –1.88
(i.e., the third percentile for height) and was categorized as
moderate (–1.88 . SDS .–3.0) or severe (,–3.0 SDS). Final
height was deﬁned as the last height measurement avail-
able after 18 years of age, or, when not available, as the last
height measurement when growth velocity per year was
below 1 cm in boys .17 years old and girls .16 years old.
Height at start of RRT was deﬁned as ﬁrst height available
within 3 months after start of RRT or within 6 weeks for
those who started RRT before 2 years of age.
To study the effect of height SDS change from start of
RRT to ﬁnal height measurement, we included only
children with a potential for catch-up growth (i.e., those
,16 years old in this study). Time on RRT was deﬁned as
the time interval between start of RRT and either the last
available height measurement or the age of 19, whichever
occurred ﬁrst. Renal diseases were grouped by primary
renal disease code for pediatric patients, according to the
ERA-EDTA Registry coding system (27).
Statistical Analyses
Patient characteristics are presented as median and
interquartile range (IQR) for continuous variables and
percentages for categorical variables. For comparison over
time, only patients from countries with a complete follow-
up of patients reaching ﬁnal height over the last two
decades were included.
Table 1. Demographic and clinical characteristics of the study
population (n=1612)
Variable Value
Sex
Male 868 (53.8)
Female 744 (46.2)
Primary renal disease
CAKUT 651 (40.4)
GN 288 (17.9)
Hereditary nephropathy 117 (7.3)
Cystic kidney disease 189 (11.7)
Hemolytic-uremic syndrome 48 (3.0)
Ischemic renal failure 22 (1.3)
Metabolic disorder 72 (4.5)
Vasculitis 54 (3.3)
Miscellaneous 93 (5.8)
Unknown or missing
(12 missing)
78 (4.8)
Median age at start of RRT (yr) 12.8 (9.0–15.6)
Age at start of RRT
0 to ,2 yr 70 (4.3)
2 to ,5 yr 98 (6.1)
5 to ,13 yr 540 (33.5)
13 to ,17 yr 713 (44.2)
$ 17 yr 191 (11.9)
Median height SDS at start
of RRT (n=915)
21.56 (–2.75 to –0.44)
Treatment modality at start
of RRT (33 missing)
Hemodialysis 648 (41.1)
Peritoneal dialysis 654 (41.4)
Transplantation 277 (17.5)
Period of start of RRT
,1990 224 (13.9)
1990–1999 693 (43.0)
2000–2011 695 (43.1)
Median age at time of ﬁnal
measurement (yr)
19.0 (18.1–20.0)
Number of RRT modalities
1 418 (25.9)
2 685 (42.5)
$3 509 (31.6)
Time on RRT at ﬁnal
height measurement
0 to ,2 yr 269 (16.7)
2 to ,5 yr 422 (26.2)
5 to ,10 yr 542 (33.6)
10 to ,15 yr 260 (16.1)
$15 yr 119 (7.4)
Median percentage of lifetime
with functioning graft
15.9 (0.0–34.7)
Treatment modality at ﬁnal
height measurement
(28 missing)
Hemodialysis 272 (17.2)
Peritoneal dialysis 145 (9.1)
Transplantation 1167 (73.7)
Unless otherwise noted, values are number (%) of patients.
Medians are accompanied by interquartile ranges. CAKUT,
congenital anomalies of the kidney andurinary tract; RRT, renal
replacement therapy; SDS SD score.
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To investigate the relationship between ﬁnal height SDS
and potential determinants, univariable and multivariable
linear regression analysis were used. Adjustments were
made for possible confounders, which were chosen on the
basis of a priori considerations and criteria for confounding
(28). Adjusted mean ﬁnal height SDS was recalculated us-
ing the distribution in all cases. Variables included in ad-
justed analyses were age at start of RRT (0 to ,2 years, 2 to
,5 years, 5 to ,13 years, and $13 years), period of start of
RRT by decade (,1990, 1990–1999, 2000–2010), country,
sex, primary renal disease category, ﬁrst modality of
RRT (HD ﬁrst, PD ﬁrst or transplantation ﬁrst), percentage
of lifetime and on RRT time on transplantation, and height
SDS at start of RRT. Statistical analyses were performed
using SAS software, version 9.2.
Results
Baseline Characteristics
Data were obtained from 1612 children receiving RRT
from 20 countries who reached adult height between 1990
and 2011. Median age at start of RRT was 12.8 years, 53.8%
of patients were male, and median age at ﬁnal height
measurement was 19.0 years (Table 1). Congenital anom-
alies of the kidney and urinary tract (CAKUT) were the
most frequent underlying disease (40.4%), followed by
glomerulonephritides (17.9%). Similar proportions of chil-
dren received PD (41.1%) and HD (41.4%) as initial RRT
modality, whereas 17.5% started with a preemptive renal
transplantation. Median time on RRT was 5.7 years (IQR,
2.9–9.4 years). At the time of ﬁnal height measurement,
73.7% of patients had a functioning renal allograft, 17.2%
were on HD, and 9.1% on PD (Table 1).
Final Height and Prevalence of Short Stature
Boys reached a median ﬁnal height of 168 cm (IQR, 161–
173 cm); median ﬁnal height SDS was –1.57 (IQR, 22.56 to
20.81). Median ﬁnal height in girls was 155 cm (IQR, 149–
161 cm); median ﬁnal height SDS for girls was –1.67 (IQR,
22.70 to 20.76). The difference between boys and girls
was not signiﬁcant (P=0.72). Overall, the median ﬁnal
height SDS was –1.65 (IQR, 22.64 to 20.78); 57.4% had
attained an adult height within the normal range, whereas
23.5% exhibited moderate (21.88 . SDS .23.0) and
19.1% severe (,23 SDS) adult height deﬁcits. At the
time of ﬁnal height measurement, body mass index values
were within the normal range in most patients, with a me-
dian of 21.2 (IQR, 19.2–24.0) in boys and 21.2 (IQR, 19.0–
24.4) in girls.
Longitudinal Trends in Final Height
In the countries with complete follow-up information in
the period 1990–2011 (n=981 patients), the overall propor-
tion of patients with an adult height in the normal range
rose from 49.6% in children who reached adulthood in
1990–1995 (median ﬁnal height, 21.90 SDS) to 62.2%
among those reaching adulthood in 2006–2011 (median
ﬁnal height, –1.41 SDS) (P=0.05) (Figure 1). Final height
SDS improved signiﬁcantly in both boys (from a median
of –1.87 in 1990–1995 to 21.32 in 2006–2011) and girls
(from a median of –2.15 in 1990–1995 to –1.67 in 2006–
2011). The trend in ﬁnal height change became more signif-
icant (from –2.06 in 1990–1995 to 21.33 SDS in 2006–2011)
after adjustment for age at start of RRT and PRD.
Furthermore, the improvement over time became clearer
when stratifying by age and period of start of RRT.
Adjusted ﬁnal height increased signiﬁcantly from 21.93
SDS (IQR, 22.13 to 21.70) in children who started RRT
before 1990, to 21.78 (IQR, 22.01 to 21.53) in children
starting RRT in 1990–1999, and to 21.61 (IQR, 21.81 to
21.34) in those commencing RRT after 1999 (P,0.001) and
the improvement in ﬁnal height over time was seen within
all categories of age at RRT start (Figure 2).
A height measurement at start of RRT was available for
566 patients (58%) in patients from countries with complete
follow-up information. The adjusted height SDS change by
year spent on RRT from start of RRT to ﬁnal height
measurement did not signiﬁcantly differ by the period of
Figure 1. | Distribution of height SDS by period of reaching adulthood (n=1612). SDS, SD score.
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start of RRT. In the early period of RRT (before 1990),
height SDS change was 20.04 per year on RRT (95% con-
ﬁdence interval [CI], 20.10 to 0.02 per year on RRT),
whereas it was 20.11 per year on RRT (95% CI, 20.26 to
20.05 per year on RRT) in a more recent period of RRT
(2001–2006). When we selected only patients who started
RRT before 16 years of age (children with growth poten-
tial), there was a signiﬁcant improvement over time in the
change in height SDS from start of RRT to ﬁnal height SDS
(Figure 3). Although not signiﬁcantly, height SDS at start
of RRT improved over time; it was 21.65 in the early pe-
riod of RRT and 21.32 upon starting RRT from 2001 to
2006 (P=0.37).
Factors Associated with Final Height
Older age at start of RRT (i.e., children $13 years of age
at start of RRT versus other age categories), a more recent
period of start of RRT (2000–2010 and 1990–1999 versus
before 1990), the percentages of lifetime on transplantation
and RRT time on transplantation, and a higher height SDS
at time of RRT start were independently associated with a
signiﬁcantly higher adjusted ﬁnal height SDS (Tables 2
and 3). For 49.4% of the children commencing RRT before
age 13 years, the ﬁnal height SDS was below 21.88. Fur-
thermore, after adjustment for sex, age, and period of start
of RRT, patients with CAKUT were signiﬁcantly shorter at
ﬁnal height than those with GN, cystic kidney diseases,
hereditary nephropathy, hemolytic-uremic syndrome, vas-
culitis, and miscellaneous causes, while patients with met-
abolic disorders were signiﬁcantly shorter than those with
CAKUT (Table 2). In the subgroup of patients with cysti-
nosis or oxalosis (n=66), the adjusted ﬁnal height SDS was
22.54 (IQR, 22.91 to 22.16).
Preemptive transplantation as initial RRT modality was
associated with a signiﬁcantly better adult height SDS as
compared with PD and HD, but after adjustment for time
on transplantation no signiﬁcant differences between initial
treatment modalities were found (Table 2).
Figure 2. | Changes in final height SD score (SDS) over time according to age and period of start of renal replacement therapy (RRT) (n=981).
The horizontal line in the middle of the box represents the median; the bottom and top of the box represent the lower and upper quartiles,
respectively; and the ends of the whiskers represent the 10th and the 90th percentiles.
Figure 3. | Mean yearly change in height SD score (SDS) from start of
renal replacement therapy (RRT) to final height measurement by
period of start of RRT (n=458). In patients who started RRTat age,16
years, the change in height SDS between start of RRTand final height
SDS significantly improved (P=0.02). Analyses were adjusted for age
at start of RRT.
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Discussion
This Europe-wide adult height study, the ﬁrst of its kind
since early reports by the ERA-EDTA Registry (29), dem-
onstrates the size of the problem of growth failure in chil-
dren with ESRD. Around 50% of the children requiring
RRT before their 13th birthday grew to a ﬁnal height be-
low the third percentile. A ﬁfth of patients with childhood-
onset ESRD attained an adult height more than 3 SDs
below the mean, a degree of stunting highly likely to affect
social integration and quality of life (5,6,30). These growth
outcomes are in keeping with data of the NAPRTCS reg-
istry (8); the slightly better mean adult height SDS ﬁgures
in the North American Registry (21.46 versus 21.65 in
this study) are largely explained by differences in the ref-
erence datasets (26), whereas absolute heights were almost
identical to or even slightly better than those in the
NAPRTCS (girls, 154 cm; boys, 166 cm) and our registry
(girls, 155 cm; boys, 168 cm).
At ﬁrst glance the analysis of longitudinal trends in
height outcomes appears disappointing, with a global
height gain of 0.49 SDS (i.e., 2.5 cm) between the patients
attaining adult height before 1995 and those who did after
2005. However, this modest improvement was clearly re-
lated to changes in population characteristics, as an in-
creasing fraction of children with early-onset ESRD due
to severe renal malformations or multisystem disease
was admitted to pediatric RRT programs and survived
to adulthood over time. Also, patients with congenital
malformations and inherited metabolic disorders
achieved a signiﬁcantly smaller adult height than patients
with disorders typically manifesting in later childhood.
After adjustment for the age at RRT start and primary re-
nal diagnosis, a more signiﬁcant 0.73 SDS increase in adult
height over time became apparent.
Multivariable analysis revealed several factors related to
the timing and choice of RRT that appear critical for ﬁnal
height outcomes in childhood-onset ESRD. The most
important predictor of an acceptable ﬁnal height was a
late need for RRT during the pediatric age. However,
height SDS did not change signiﬁcantly between onset of
RRT and ﬁnal measurement. The overall effect of RRT on
ﬁnal height was neutral throughout the observation period,
Table 2. Factors associated with final height SD score: categorical variables (n=1612)
Variable
Unadjusted Adjusted
Mean Final Height
SDS (95% CI) P Value
a Mean Final Height
SDS (95% CI) P Value
a
Sex
Male 21.80 (21.91 to 21.70) Reference 21.79b
Female 21.77 (21.92 to 21.62) 0.68 21.79 (21.93 to 21.64)b 0.94
Age at start of RRT
$17 yr 21.49 (21.60 to 21.39) Reference 21.48 Reference
13 to ,17 yr 21.55 (21.79 to 21.30) 0.08 21.60 (21.85 to 21.35)c 0.33
5 to ,13 yr 22.03 (22.27 to 21.78) ,0.001 21.95 (22.21 to 21.69)c ,0.001
2 to ,5 yr 22.26 (22.63 to 21.89) ,0.001 22.17 (22.57 to 21.78)c ,0.001
0 to ,2 yr 22.16 (22.58 to 21.75) ,0.001 22.16 (22.60 to 21.71)c 0.003
Period of start of RRT
,1990 22.40 (22.60 to 22.20) Reference 22.17 Reference
1990–1999 21.84 (22.06 to 21.61) ,0.001 21.76 (21.99 to 21.53)d ,0.001
2000–2010 21.54 (21.86 to 21.32) ,0.001 21.70 (21.95 to 21.44)d ,0.001
Treatment at start of RRT
Peritoneal dialysis 21.91 (22.02 to 21.79) Reference 21.86
Hemodialysis 21.73 (21.89 to 21.56) 0.03 21.81 (21.99 to 21.62)d 0.52
Transplantation 21.65 (21.86 to 21.43) 0.02 21.57 (21.80 to 21.41)e 0.006
Primary renal disease
CAKUT 22.00 (22.12 to 21.88) Reference 22.01 Reference
GN 21.52 (21.73 to 21.31) ,0.001 21.56 (21.77 to 21.36)f ,0.001
Hereditary nephropathy 21.46 (21.76 to 21.16) ,0.001 21.30 (21.60 to 21.01)f ,0.001
Cystic kidney disease 21.75 (22.00 to 21.51) 0.05 21.70 (21.95 to 21.46)f 0.01
Hemolytic-uremic syndrome 21.41 (21.86 to 20.96) 0.01 21.28 (21.72 to 20.84)f 0.001
Vasculitis 21.19 (21.61 to 20.77) ,0.001 21.33 (21.74 to 20.92)f 0.001
Metabolic disorder 22.59 (22.93 to 22.22) 0.002 22.55 (22.91 to 22.19)f 0.003
Miscellaneous 21.59 (21.89 to 21.29) 0.008 21.61 (21.90 to 21.31)f 0.008
SDS, SD score; CI, conﬁdence interval; RRT, renal replacement therapy; CAKUT congenital anomalies of the kidney and urinary tract.
aDifference from reference population.
bAdjusted for age at start of RRT and period of RRT.
cAdjusted for period of RRT, sex, and primary renal disease.
dAdjusted for age at start of RRT and primary renal disease.
eAdjusted for age at start of RRT, period of RRT, sex, and primary renal disease.
fAdjusted for age at start of RRT, period of RRT, and sex.
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among the overall population. Moreover, height at start of
RRT increased by 0.4 SDS from the early period to the more
recent years of starting RRT. This would suggest that the
observed moderate improvement of ﬁnal height over time
was mainly due to better growth management during the
pre-ESRD period and that any strategies to prevent or
correct CKD-associated growth failure (31–34) are most
likely to be effective before ESRD has occurred. However,
when we analyzed only patients with a greater “growth
potential” on RRT, namely only the patients ,16 years of
age at start of RRT, the change between height at start and
ﬁnal height measurement signiﬁcantly improved over time
(Figure 3). This ﬁnding that height SDS no longer declines
after RRT also suggests overall improvement in the care of
ESRD over the years.
Regarding the choice of RRT once required, the fraction
of childhood lifetime spent on dialysis adversely predicted
ﬁnal height. This ﬁnding is consistent with reported
longitudinal data on growth on dialysis demonstrating a
decrease in height SDS over time (1,8), and the negative
effect of the fractional lifetime spent on dialysis on adult
height previously noted in patients receiving long-term
recombinant human growth hormone (rhGH) therapy
(34). Conversely, the time spent with a functioning allo-
graft was positively associated with ﬁnal height outcome.
In our study, no data on dose and duration of rhGHwere
available to estimate its effect on ﬁnal height, but we found
that only a small proportion of the population (approxi-
mately 20%) has been treated by rhGH while receiving
RRT. Although previous reports suggested a positive effect
of rhGH on ﬁnal height in children with CKD (34,35) and
support its use during RRT, it is noteworthy that the cur-
rently approved European indication for the drug is
limited to patients undergoing dialysis and allograft recip-
ients with impaired GFR.
Further research will be required to develop optimiza-
tion strategies that will facilitate better growth outcomes in
this challenging population.
This study has several limitations. The lack of detailed
data on treatments such as steroids, supplemental feeding,
and rhGH precluded an assessment of the relative effect of
these therapies on ﬁnal height. We also did not have
sufﬁcient information on ethnicity, syndromic short stat-
ure, or comorbid conditions that inﬂuence growth and ﬁnal
height (36), nor did we have data on pubertal status or
mid-parental height. Also, one might imagine that chil-
dren who died were more likely to be shorter than those
who survived and reached ﬁnal height (4). Finally, al-
though adult height has been assessed at an average age
of 19 years, some patients might not have reached their
deﬁnite ﬁnal height at last measurement. Indeed, delayed
puberty has been associated with late growth after age 18
in children with ESRD (11,37). This ﬁnding, however, has
not been reported in more recent studies reporting normal
puberty after transplantation (38). The strengths of the
study include the large data set; the long-term follow-up,
including complete coverage of sequential RRT modalities;
and the rather detailed patient characterization, all of
which allow a comprehensive analysis of potential effec-
tors of ﬁnal height. Even if we cannot fully ascertain case
completeness in the ESPN/ERA-EDTA Registry, most na-
tional registries have speciﬁc procedures ensuring data
quality and coverage.
In conclusion, although more and more challenging
pediatric patients have been accepted into RRT programs,
including neonates and children with severe comorbid
Table 3. Factors associated with final height SD score: continuous variables (n=1612)
Variable
Unadjusted Adjusted
Mean Final Height
SDS (95% CI) P Value
Mean Final Height
SDS (95% CI) P Value
Height at start of RRT
Per 1 SDS increase 0.38 (0.34 to 0.43) ,0.001 0.37 (0.32 to 0.41)a ,0.001
Percentage of lifetime RRT
Per 10% increase 20.09 (–0.12 to 20.06) ,0.001 0.04 (20.01 to 0.09)b 0.11
Percentage of lifetime with
functioning graft
Per 10% increase 0.008 (–0.03– to 0.04) 0.64 0.19 (0.15 to 0.24)b ,0.001
Percentage of RRT time with
functioning graft
Per 10% increase 0.06 (0.04 to 0.08) ,0.001 0.10 (0.07 to 0.12)b ,0.001
Years with functioning graft
Per additional year 0.004 (20.01 to 0.02) 0.62 0.10 (0.08 to 0.12)b ,0.001
Percentage of RRT time
on dialysis
Per 10% increase 20.06 (20.08 to –20.04) ,0.001 20.10 (20.12 to –0.08)b ,0.001
Years on dialysis
Per additional year 20.16 (20.19 to 20.13) ,0.001 20.14 (20.17 to –0.11)b ,0.001
SDS, SD score; CI, conﬁdence interval; RRT, renal replacement therapy.
aAdjusted for age at start of RRT, period of RRT, sex, and primary renal disease.
bAdjusted for age at start of RRT, period of RRT, sex, primary renal disease, and initial RRT modality.
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conditions, ﬁnal height has consistently improved over the
years. New approaches are needed to improve longitudinal
growth and adult height prognosis after childhood-onset
ESRD.
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